TICKERNERD
Menu
BBIOBBIOHealthcare · Biotechnology

BBIO Stock Forecast: BridgeBio Pharma, Inc. Price Predictions for 2026-2027

Last close, 15 Oct 2026
$67
+3.37% on the day

The 22 Wall Street analysts covering BridgeBio Pharma, Inc. hold a median 12-month price target of $110 — +63.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$12.4B
Ticker Nerd rank
67 / 100
Median analyst target
$110
Analysts covering
22
Revenue$243.7M+120.4% y/y
Operating income−$107.1M
Net income−$155.9M
Free cash flow−$71.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.2%
1M
−1.8%
YTD
−12.2%
1Y
+18.5%
From 52W high
−25.6%
From 52W low
+26.1%
$53
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BridgeBio Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Value
92
Volatility
88
Quality
78
Momentum
74
Accruals
48
Revisions
48
Size
13
Issuance
13

Growth (92): Sales and profits are climbing, and climbing faster than before.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26BBIOHigh $156Median $110Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
20 Buy2 Hold0 Sell
Low $80Median $110High $156

The green dot is the last close — the median target sits +63.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Oct 2026BarclaysMaintainsOverweight$157 → $156
10 Sept 2026HC Wainwright & Co.ReiteratesBuy—
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
2 Sept 2026HC Wainwright & Co.ReiteratesBuy—
2 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
1 Sept 2026MizuhoMaintainsOutperform—
1 Sept 2026MizuhoMaintainsOutperform$96 → $110
12 Aug 2026Canaccord GenuityMaintainsBuy—
12 Aug 2026Canaccord GenuityMaintainsBuy$104 → $106
12 Aug 2026JP MorganMaintainsOverweight$100 → $111
12 Aug 2026JP MorganMaintainsOverweight—
12 Aug 2026Truist SecuritiesMaintainsBuy—
12 Aug 2026Truist SecuritiesMaintainsBuy$102 → $107
11 Aug 2026B of A SecuritiesMaintainsBuy$101 → $104
11 Aug 2026B of A SecuritiesMaintainsBuy—
11 Aug 2026Morgan StanleyMaintainsOverweight$98 → $97
11 Aug 2026Morgan StanleyMaintainsOverweight—
11 Aug 2026Piper SandlerMaintainsOverweight$111 → $115
11 Aug 2026Piper SandlerMaintainsOverweight—
11 Aug 2026TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Oct 2026, BridgeBio Pharma, Inc. returned +18.5% against +17.3% for the S&P 500, dividends included.

BBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26BBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
8
Fundamentals

BridgeBio Pharma, Inc. (BBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.7×

Cheaper than 96% of US stocks

Price / sales
17.4×

Cheaper than 10% of US stocks

Price / book
−4.9×

Cheaper than 97% of US stocks

EV / EBITDA
−31.8×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
120.4%

Higher than 94% of US stocks

Earnings growth (YoY)
120.4%

Higher than 86% of US stocks

Gross margin
93.8%

Higher than 98% of US stocks

Operating margin
−43.9%

Higher than 18% of US stocks

Net margin
−97.0%

Higher than 6% of US stocks

Returns & dividend
Return on equity
34.9%

Higher than 90% of US stocks

Return on assets
−26.0%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BridgeBio Pharma, Inc. (BBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BridgeBio Pharma, Inc. has a market value of $12.4B and an enterprise value of $15.0B.

  • Revenue in the twelve months to 30 June 2026: $713.1M. The latest quarter grew 120.4% year on year.

  • Net income over the same four quarters: −$702.0M, a −98.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.57.

  • Free cash flow in the twelve months to 30 June 2026: −$437.8M.

  • BridgeBio Pharma, Inc. spent $228.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 195.3M.

  • Trailing P/E: −16.7×; forward P/E: −247.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BridgeBio Pharma, Inc. employs 999 people — $714K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

BBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BBIOBridgeBio Pharma, Inc.$12.4B
67
CORTCorcept Therapeutics, Inc.$12.5B
69
SMMTSummit Therapeutics, Inc.$12.1B
33
JAZZJazz Pharmaceuticals Plc$13.2B
99
HALOHalozyme Therapeutics, Inc.$13.3B
98
ASNDAscendis Pharma A/S$13.9B
84
TECHBio-Techne Corp.$11.3B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BridgeBio Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBIO news & analysis

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

Seeking Alpha · 13 Oct 2026positive

Seeking Alpha reports that BridgeBio delivered Q2 2026 net revenues of $243.7 million, compared with $110.6 million a year earlier, despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates from late 2026 to mid-2027.

Why it matters — The revenue increase and multiple pending FDA reviews are notable developments for investors tracking BridgeBio's performance and pipeline.

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

Zacks Investment Research · 7 Oct 2026positive

The FDA granted priority review to BridgeBio Pharma’s filing for infigratinib, an oral therapy for achondroplasia.

Why it matters — The review designation is relevant to BBIO watchers because infigratinib could become the first approved oral therapy for achondroplasia.

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

GlobeNewsWire · 6 Oct 2026positive

BridgeBio announced that one oral presentation, three rapid-fire oral presentations and six posters on acoramidis in people with ATTR-CM will be presented at the HFSA Annual Scientific Meeting, October 9–12, 2026. The company said the data include independent comparative real-world EHR data.

Why it matters — The presentations will share additional acoramidis data relevant to BBIO watchers following its ATTR-CM program.

FAQ

Frequently asked questions about BBIO stock

What is the BBIO stock price forecast for 2026-2027?

The 22 Wall Street analysts covering BridgeBio Pharma, Inc. have a median 12-month price target of $110, with estimates ranging from $80 to $156. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBIO stock a buy right now?

Of the 22 analysts covering BridgeBio Pharma, Inc., 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BridgeBio Pharma, Inc. 67 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBIO?

As at 14 Oct 2026, BridgeBio Pharma, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will BBIO stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +63.9% from the last close, and Ticker Nerd's factor model ranks BridgeBio Pharma, Inc. 67 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBIO stock forecast for 2030?

No analyst covering BridgeBio Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $156 over the next 12 months.

How has BBIO stock performed over the past year?

BridgeBio Pharma, Inc. returned +18.5% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BridgeBio Pharma, Inc. do?

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions.

What is the latest news on BBIO?

The most recent item we track (Seeking Alpha, 13 Oct 2026): "BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews". Seeking Alpha reports that BridgeBio delivered Q2 2026 net revenues of $243.7 million, compared with $110.6 million a year earlier, despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates from late 2026 to mid-2027.

Company

About BridgeBio Pharma, Inc.

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.

CEO Dr. Neil Kumar Ph.D. · 999 employees · United States · https://bridgebio.com